Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD

Summary

This study purpose is to further study the profiles of glycopyrronium (NVA237) and tiotropium during the first hours after dosing and their impact on pulmonary function, COPD symptoms and ability to perform daily activities by the patient.

Timeline

Start

2014-02

Primary completion

2014-10

Completion

2014-10

Outcome

Met primary endpoint

registry Glycopyronium From Sequence A to B and Sequence B to A vs Tiotropium From Sequence A to B and Sequence B to A; p = 0.0250 NCT01959516 ↗

Drugs

Indications